Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Bioventus (BVS) EBIAT (2020 - 2025)

Bioventus' EBIAT history spans 6 years, with the latest figure at $14.8 million for Q4 2025.

  • For Q4 2025, EBIAT rose 2546.93% year-over-year to $14.8 million; the TTM value through Dec 2025 reached $23.6 million, up 163.84%, while the annual FY2025 figure was $22.7 million, 148.32% up from the prior year.
  • EBIAT reached $14.8 million in Q4 2025 per BVS's latest filing, up from $4.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $14.8 million in Q4 2025 to a low of -$100.0 million in Q2 2023.
  • Average EBIAT over 5 years is -$17.0 million, with a median of -$4.5 million recorded in 2021.
  • Peak YoY movement for EBIAT: crashed 179392.0% in 2022, then skyrocketed 2546.93% in 2025.
  • A 5-year view of EBIAT shows it stood at -$25000.0 in 2021, then plummeted by 179392.0% to -$44.9 million in 2022, then plummeted by 46.16% to -$65.6 million in 2023, then soared by 99.08% to -$603000.0 in 2024, then surged by 2546.93% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's EBIAT are $14.8 million (Q4 2025), $4.0 million (Q3 2025), and $7.5 million (Q2 2025).